Current approach to Waldenström Macroglobulinemia.

Abstract excerpt

Waldenström Macroglobulinemia (WM) is a unique, low grade, IgM lymphoplasmacytic lymphoma with a heterogeneous clinical course. A paucity of high-grade evidence from large phase 3 trials remains a major issue in the field despite a rapidly expanding therapeutic armamentarium against WM. Prior knowledge of the patients' MYD88L265P and CXCR4 mutation status aids in treatment decision making if Bruton's tyrosine...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Molecular Targeted Therapy
• Share to Mutation
• Share to Myeloid Differentiation Factor 88